Aldesleukin Completed Phase 2 Trials for Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01266603High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
NCT00204581Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases